Amjevita Fact Sheet

Amjevita (adalimumab-atto) is a biosimilar for the biologic medication Humira (adalimumab). A biosimilar is a U.S. Food and Drug Administration (FDA) approved biologic product that is very similar to an already FDA-approved biologic.

Get your free resource and learn more about:

  • How Amjevita works
  • People who can take Amjevita
  • Common side effects and possible risks

Resource last updated: January 2025

Fill out the form below to download your free resource. You will also receive an email with the download link.





Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2025 National Psoriasis Foundation/USA


The National Psoriasis Foundation is a qualified 501(c)(3) EIN 93-0571472.


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.